CDC Working Group Doesn't Back Genetic Test for Depression Treatment Efficacy

The independent Evaluation of Genomic Applications in Practice and Prevention Working Group has issued its first recommendation, saying it found insufficient evidence to support a recommendation for or against use of CYP450 testing in adults who are beginning treatment with selective serotonin reuptake inhibitors (SSRIs), which are the first-line choice for drug therapy in the United States. The statement says the CYP450 family of enzymes is a major subset of all drug-metabolizing enzymes, and testing for it could guide treatment for the large number of patients suffering depression, with individualized treatment possibly reducing lost work and school days and improving patients' quality of life. Other factors, including diet and medications, also affect SSRI metabolism, it notes.

A Dec. 19 news CDC release quoted Muin J. Khoury, M.D., Ph.D., director of the National Office of Public Health Genomics at the Centers for Disease Control and Prevention (this office created the working group in 2005), and said the recommendation statement has been published in the December issue of Genetics in Medicine and is available at www.egappreviews.org. "With the expected increase in the number of genetic tests in practice, this recommendation statement from the working group marks the beginning of a sustained public health approach to independent assessment of genomic applications in clinical and public health practice. The multidisciplinary EGAPP Working Group prioritizes and selects tests for review, considers the available evidence, provides recommendations on appropriate use of genetic tests in specific clinical scenarios, and highlights critical knowledge gaps," Khoury said.

The working group's statement says its member found no evidence linking testing for CYP450 to clinical outcomes in adults treated with SSRIs. Some studies of a single dose of SSRI in healthy patients reported an association, but this was not supported by studies of patients receiving ongoing SSRI treatment, according to the seven-page statement. "In the absence of evidence supporting clinical utility, it is not known if potential benefits from CYP450 testing will outweigh potential harms," it states. "Potential harms may include increased cost without impact on clinical decision making or improvement in patient outcomes, less effective treatment with SSRI drugs, or inappropriate use of genotype information in the management of other drugs metabolized by CYP450 enzymes."

Download Center

HTML - No Current Item Deck
  • Safety Management Software - Free Demo

    IndustrySafe Safety Software’s comprehensive suite of modules help organizations to record and manage incidents, inspections, hazards, behavior based safety observations, and much more. Improve safety with an easy to use tool for tracking, notifying and reporting on key safety data.

  • Create Flexible Safety Dashboards

    IndustrySafe’s Dashboard Module allows organizations allows you to easily create and view safety KPIs to help you make informed business decisions. Our best of breed default indicators can also save you valuable time and effort in monitoring safety metrics.

  • Schedule and Record Observations

    IndustrySafe's Observations module allows managers, supervisors, and employees to conduct observations on employees involved in safety critical behavior. IndustrySafe’s pre-built BBS checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Why Is Near Miss Reporting Important?

    A near miss is an accident that's waiting to happen. Learn how to investigate these close calls and prevent more serious incidents from occurring in the future.

  • Get the Ultimate Guide to Safety Training

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common FAQs.

  • Industry Safe
comments powered by Disqus

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2019

    June 2019

    Featuring:

    • ASSP SAFETY 2019 PREVIEW
      New Orleans Networking
    • NATION SAFETY MONTH
      Heed These Summer Safety Tips
    • TRAINING
      Education, Skill Development, and Behavior Change
    • SAFETY MANAGEMENT
      What Good Looks Like
    View This Issue

Bulwark Quiz